Introduction: We retrospectively analyzed 6 cases of adrenal cortical carcinoma (ACC) treated during a 12-year period at a single institution. Patients and Methods: We reviewed the clinical and pathological records and updated the follow-up of the patients treated and observed in our institution between 1995 and 2006. Results: All 6 patients underwent surgery for ACC. The mean age at diagnosis was 53.3 years (range 36–72). The median follow-up was 50.7 months (range 13–132). Three patients were clinically classified as stage II, 2 as stage III and 1 as stage IV with bone metastasis. The 5-year overall survival was 62.5%. Recurrences or metastases occurred in 4 patients. Two patients without reoperation for metastases died, and others with radical treatments such as surgery, chemotherapy, transcatheter arterial embolization and/or radiation remain alive. Conclusions: In our experience, transcatheter arterial embolization was effective against liver metastasis.

Keywords:
Adrenal cortical carcinoma, Transcatheter arterial embolization, Long-term survival
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.